Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041696 | 0.87 | SLC6A9 (0.75) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5040981 | 0.86 | SLC6A9 (0.70) | SLC6A9KCNH2SLC6A5PKMSLC6A7 | |
| SCHEMBL5043451 | 0.84 | SLC6A9 (0.59) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4435757 | 0.82 | SLC6A9 (0.67) | SLC6A9PKMSLC6A7CA12CA1 | |
| SCHEMBL5041148 | 0.80 | SLC6A9 (0.77) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5047471 | 0.80 | SLC6A9 (0.77) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL27669155 | 0.79 | SLC6A9 (0.79) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5043147 | 0.79 | SLC6A9 (0.79) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5037687 | 0.78 | SLC6A9 (0.69) | SLC6A9KCNH2 | |
| SCHEMBL5040921 | 0.77 | SLC6A9 (0.59) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |